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Patients with chronic obstructive pulmonary disease (COPD) may demonstrate great variability between results on 
the pulmonary function test (PFT) compared to those on the cardiopulmonary exercise test (CPXT). The purpose 
of this study was to correlate PFT and CPXT indices and to identify PFT threshold values for predicting exercise 
capacity in patients with airflow limitation. Fifty-seven patients (48 men and 9 women) of mean age 66.4 & 4.8 years 
with COPD and 40 age-matched control patients underwent PFT and CPXT. Based on the CPXT results, the 
patients were divided into ventilatory-limited (VL) and nonventilatory-limited (NVL), and the findings were 
correlated with the PFT indices. Linear regression analysis was used to determine the relationship between dyspnea 
index ( VE,,,/MVV) and forced expiratory volume in one second (FEV,). The cutoff value for VL was FEV, ~38% 
and for NVL FEV, >68%. The prominent limiting symptom (61%) in the VL group was dyspnea sensation, with leg 
discomfort presenting in only 14%; corresponding rates in the NVL group were 38% and 31%. We conclude that the 
FEV, is a reliable index for distinguishing VL from NVL COPD patients during CPXT at two extremes: below 38% 
of the predicted value (VL) and above 68% of the predicted value (NVL). 
RESPIR. MED. (1998) 92, 1245-1250 
Introduction 
Patients with pulmonary and cardiac disorders are 
handicapped by dyspnea and exertional discomfort, which 
may limit exercise performance. However, it is often diffi- 
cult to distinguish the origin of these symptoms from 
historical and clinical information (1). In most cases, ven- 
tilatory symptoms (i.e. dyspnea) contribute to the exercise 
limitation in chronic obstructive pulmonary disease 
(COPD) patients with moderate to severe degree (2,3). Leg 
discomfort, on the other hand, more typically plays a role 
in cardiovascular-related disease, where oxygen supply (i.e. 
cardiac output) lags behind the oxygen demand of the 
exercising muscles (4,5). However, in many patients, the 
pulmonary function test (PFT) and cardiac evaluation (i.e. 
stress test, electrocardiogram, blood pressure) results are 
inconclusive (6), and a supplementary cardiopulmonary 
exercise test (CPXT) by gas exchange is necessary. 
The predicted exercise ventilatory capacity is determined 
by the maximal voluntary ventilation (MVV) and the 
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forced expiratory volume in one-second (FEV,) obtained 
during PFT. Although FEV, is the pulmonary function 
index that best correlates with maximum exercise minute 
ventilation (VE,,,) (7), its predictive value for exercise 
outcome is unclear (8,9). Using stepwise regression analysis, 
Pineda et al. (10) showed that the FEV, could account for 
only 56% of the variance in oxygen consumption (VO,) in 
patients with mild to moderate COPD (FEV, ~76 ZIZ 15% of 
predicted). Cotes and colleagues (11) found that in patients 
whose exercise capacity was limited by respiratory factors, 
the limitation could not be accurately predicted by FEV,, 
forced vital capacity (FVC), and single breath diffusion 
lung capacity for carbon monoxide (DLCO). Owens and 
coworkers (12) however, reported that DLCO was a more 
sensitive and specific predictor of exercise desaturation than 
FEV, Recently, Killian et al. (13) noted that in 3 1 patients 
with chronic airway limitation (i.e. FEV, ~40% of pre- 
dicted), 11 had leg fatigue as the limiting cause of exercise. 
Thus, owing to the multifactorial nature of exercise limita- 
tion in COPD patients, the prediction of exercise capacity is 
often difficult and cannot be based solely on the degree of 
airflow obstruction as determined by the PFT. 
Since many patients with COPD present with a great 
variability in lung function, the identification of a cutoff 
pulmonary function value that identifies the pulmonary 
system as the primary cause of the exercise limitations can 
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have important clinical implications. This is particularly 
valid in impairment/disability evaluation and in patients 
with heart-lung disease in whom the management course is 
complicated. 
The purpose of the present study was to correlate the 
PFT indices with the CPXT indices and the subjective 
symptomatology, and to identify the PFT threshold value 
that best predicts exercise limitation in COPD patients with 
different degrees of airflow limitation. 
Mythods 
SUEiJECTS 
Fifty-seven patients (48 men and 9 women) of mean age 
66.4 f. 4.8 years took part in the study. The patients were 
recruited over a period of 6 months from referrals to the 
Chest Clinic of Rabin Medical Center. All had a mild to 
severe degree of airflow obstruction and met the American 
Thoracic Society criteria for COPD (14). The FEV, ranged 
between 23% and 78% of predicted (51.6 i 12.3% of pre- 
dicted). Patients with known cardiovascular disease or any 
other systemic disease were excluded. Forty healthy sub- 
jects (32 men and 8 women) of a mean age 651-+ 5.7 years 
served as the control group. 
STUDY DESIGN 
On arrival to the exercise physiology laboratory, the par- 
ticipants were informed about the procedure and a written 
consent was obtained. All patients underwent complete 
PFT at the first visit, and thereafter within 14 days CPXT 
by gas exchange. The PFT included spirometry, lung 
volumes, maximal voluntary ventilation (MVV) and 
diffusion capacity by single breath technique. For calibra- 
tion, a 3-l syringe was used at the beginning of each session 
on each day. PFT measurements were corrected for body 
temperature and pressure saturated (BTPS). PFT was per- 
formed with a Medical Graphics Pulmonary Function 
System (1070-series 2, St. Paul, MN, U.S.A.). Lung vol- 
umes were obtained by body plethysmography (model 
1085, Medical Graphics, St. Paul, MN, U.S.A.). MVV was 
assessed by asking the patient to breathe simultaneously as 
fast and as deep for 12 s. DLCO was performed with gas 
mixture that contained air, 10% helium, and 0.3% carbon 
monoxide. Each DLCO measurement was adjusted to stan- 
dard temperature and pressure, and corrected for breath- 
holding time and effective alveolar volume as determined by 
inspired vital capacity. DLCO values were not corrected for 
hemoglobin or smoking history. The predicted values of the 
parameters were obtained from the regression equations of 
the European Community for Coal and Steel (15). 
EXERCISE PROTOCOL 
Exercise protocol was conducted between 0830h-1200h in 
the morning. Patients were encouraged to take medications 
regularly. Each participant (patients and controls) under- 
went an incremental exercise test according to the protocol 
of Wasserman et aZ. (3) on an electrically braked cycle 
ergometer (Ergoline 800). After a 3-min rest period, the 
subjects performed unloaded paddling at a rate of 60 rpm. 
The effort was then progressively increased by 15 W min - ’ 
until the subject/patient could no longer maintain a cycling 
frequency of 40 rpm. Dyspnea was defined as ‘the sensation 
of labored or difficult breathing’ and leg effort as ‘the 
sensation of leg difficulty during pedaling’. At the end of 
each test, the subjects were asked the reason for stopping 
exercise; dyspnea, leg fatigue, combined dyspnea and leg 
fatigue, or undetermined and the reason was documented. 
Cardiopulmonary data were collected by a metabolic unit 
(CPX, Medical Graphics, St. Paul, MN, U.S.A.). Heart 
rate (HR), maximum minute ventilation (VE,,,), oxygen 
consumption (VO,), carbon dioxide production (VCO,), 
oxygen pulse (0,P) and oxygen saturation (SaO,) were 
recorded continuously. Blood pressure was measured at 
rest, every 2 min, and at peak exercise. Anaerobic threshold 
(AT) by locating the change in the VEIVO, slope as de- 
scribed by Wasserman et al. (3). Dyspnea index (I/E,,,/ 
MW), expressed in per cent, and ventilatory reserve 
(MVV- vEm,,), expressed in litres, were calculated manually. 
CRITERIA FOR VENTILATORY LIMITATION 
After obtaining the CPXT results, the COPD patients were 
divided into two subgroups: ventilatory limited (VL) and 
nonventilatory limited (NVL). Ventilatory limitation was 
defined as: (1) VE,,,/MVV >80%; (2) MVV- VE,,, c 12 1 
min-I; (3) maximal heart rate (HR,,,) ~90% of the 
predicted. Our approach for VL classification (i.e. very 
small ventilatory reserve and significant cardiac reserve at 
peak exercise) was based on Wasserman (3) and Weisman 
& Zeballos (16); only patients who fulfilled all three criteria 
were included in the VL subgroup. 
DATA ANALYSIS 
The results obtained were expressed as mean and one 
standard deviation below and above the mean (rt SD). The 
student’s t-test was used to compare the PFT and CPXT 
results between COPD patients and controls. A linear 
regression analysis was applied to determine the relation- 
ship of DrCO and FEV, with VE~,,/MVV (17). Differences 
between means were considered significant at PcO.05. 
Results 
The COPD patients and the healthy controls subjects had a 
similar anthropometric profile for age (mean 66.4 & 4.8 and 
65.1 & 5.7 for controls, respectively), weight (mean 
71.3 i 6.4 kg and 74.5 * 7.2 kg, respectively) and height 
(173.5 + 4.4 cm and 176.4 * 6.8 cm, respectively). Table 1 
shows the PFT and CPXT data for both groups. 
PULMONARY FUNCTION PARAMETERS 
As expected, the COPD patients demonstrated significantly 
different pulmonary function results for FEV, (P<O.OOl), 
PULMONARY FUNCTION IN COPD 1247 
TABLE 1. Resting pulmonary function and cardiopulmonary exercise test data (mean + SD) 
Parameters 
COPD patients 
(n=57) 
Controls 
(n=40) P value* 
FEV, (% pred) 51.6 & 12.3 101.0 5 13.0 <O.OOl 
RV/TLC (% pred) 120&24 102.0 * 22.0 co.05 
DLCO (% pred) 75.9 =k 24.1 107.0 rt 16.0 <0~001 
MW (% pred) 52.3 & 18.2 106.0 zt 24.7 <O.OOl 
VO, (ml kg - ’ min ~ ‘) 21.7 f 7.0 28.8 * 4.5 <O.OOl 
VO, (% pred) 83.1 III 27.0 108.8 f- 17.1 <0~0001 
AT (% pred) 51.2 z!= 11.8 60.1 f 10.6 co.01 
0,P (% pred) 92.5 •t 24.1 120.7 zk 27.2 ~0~001 
HR,,, (“XI pred) 94.7 f 9.8 106.5 & 11.8 co.05 
~ W,,, (1 min ‘) 45.0 zt 10.1 63.8 f 14.9 co.001 
VE,,,/MVV (%) 83.6 ?c 14.4 58.2 =k 12.6 ~0~0001 
*P values ~0.05 were considered significant. 
TABLE 2. Pulmonary function test and cardiopulmonary exercise test data in ventilatory-limited and 
nonventilatory-limited patients with COPD (mean & SD) 
Parameters (28) 
NVL 
(n=29) P values* 
FEV,(%) 41.5 & 28.2 60.3 f 29.3 <0~0001 
RVITLC (%) 168.5 I!Z 35.7 149.5 zt 37.2 co.05 
DLCO (%) 68.9 zt 12.2 84.6 zt 16.3 co.05 
MVV (1 min - ‘) 42.8 zk 22.2 63.2 k 25.6 ~0~001 
MVV (%) 42.3 z!c 16.5 63.1 zt 19.8 <O.OOl 
VO,max (ml kg ~ ’ min - ‘) 19.6 f 5.2 23.5 zt 4.8 co.01 
vo, (%) 75.3 It 20.0 90.4 f 18.0 co.01 
AT (% pred of VO, max) 49.4 zt 9.2 52.8 zk 12.1 ns. 
0,P (% pred) 89.4 zt 26.8 93.0 * 22.0 n.s. 
HRmax (% pred) 82.4 k 6.1 98.3 zt 11.3 <O.OOl 
VE(1 min-‘) 41.2 rt 10.3 48.1 f 9.3 co.05 
VE,,,/MVV (%) 96.3 z!z 15.5 76.5 zk 12.8 <O.OOl 
*P values ~0.05 were considered significant. 
residual volume/total lung capacity (RV/TLC) (P<O.O5), 
DLCO (P<O.OOl), and MVV (P<O.OOl), from the controls. 
A FEV, value < 60% of the predicted value identified 26 of 
the 28 VL patients (93% sensitivity). Four of the 30 patients 
with FEV, of ~60% of predicted were not VL (87% 
specificity). 
CARDIOPULMONARY EXERCISE DATA 
Compared with the control subjects, the COPD patients 
had significantly lower VO, (P<O.OOl), AT (anaerobic 
threshold) (PcO.01) 0,P (PCO.OOl), VE,,, (P<O.Ol), and 
Hkax (P<O.O5), but significantly higher VE-JMVV 
(P<O.OOOl) (Table 1). Division of the COPD patients into 
VL (n=28) and NVL (n=29) subgroups (Table 2) yielded a 
significantly lower (P<O.O5-0.001) pulmonary function 
profile (FEV,, RV/TLC, DLCO, MVV), (P<O.O5-0.001) 
significantly iower HR,,, and VE,,, at peak exercise 
(P<O.O5-0.001) and significant higher VE,,,/MVV 
(P<O.OOl) in the VL patients. There were no significant 
differences between the subgroups in the cardiovascular 
parameters (AT,O,P). There was a significant correlation 
between the dyspnea index (VE,,,/MVV) and FEV, 
[Y= - 0.49; P<O.OOl; (Fig. l)] and between the dyspnea 
index and DLCO [Y= - 0.47; P<O.Ol; (Fig. 2)]: When we 
tried to distinguish the patients with COPD in whom 
VIZ~,,/MVV was 280% and MVV- VE,,, was < 12 1 min - ’ 
(n=35), the line at 90% of the predicted HR separated only 
28 patients who met all three criteria for VL. We were 
unable to identify a similar range for DLCO in these 
patients, as some (n=7) had a DLCO > 100% of predicted. 
However, almost all the VL patients had a FEV, ~60% 
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FIG. 1. Relationship between dyspnea index and FEV, in 
patients with COPD (n=57). r= - 0.494; P<O.OOl. 
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FIG. 2. Relationship between dyspnea index and lung 
diffusion capacity in patients with COPD (n=57). 
r= - 0.473; PCO.01. 
(only two had FEV, >60% but ~70%). All patients who 
were diagnosed with COPD and who had a FEV, ~38% 
were VL. 
Table 3 shows the limiting symptoms during CPXT in the 
57 patients and 40 controls. Dyspnea sensation was the 
main limiting symptom in patients who were classified as 
VL (60.7%), whereas local leg fatigue was the major limit- 
ing factor in the controls (47.5%). In some cases (9 patients 
and 7 controls), we were unable to determine the limiting 
symptoms. 
Discussion 
The role of CPXT in the evaluation of disability and 
impairment in patients with respiratory disorders has been 
growing in the last decade (18,19). Although PFT remains 
the more commonly used modality, the wide range of 
exercise capacity even in patients with similar severity of 
airflow limitation strengthens the argument that resting 
measurements of FEV, and DLCO are poor predictors of 
exercise capacity in patients with different degrees of COPD 
(20). 
The purpose of this study was to determine if the resting 
PFT profile correlates with the CPXT results, particularly 
in patients who are ventilatory limited, and to determine a 
pulmonary function threshold under which the pulmonary 
system is likely to be the limiting factor, even during CPXT. 
TABLE 3. Limiting symptoms for exercise termination 
No of patients (%) 
Symptoms 
Controls 
(28) (nN=zG;) (n=40) 
Leg discomfort 4 (14.3) 9 (31.0) 19 (47.5) 
Dyspnea 17 (60.7) 11 (37.9) 6 (15.0) 
Leg discomfort + dyspnea 4 (14.3) 3 (10.3) 8 (20.0) 
Undetermined 3 (10.7) 6 (10.7) 7 (17.5) 
The major findings of the study were as follows: (1) FEV, 
can distinguish VL from NVL COPD patients during 
CPXT in two extremes: when FEV, is below 38% of 
predicted-VL patients, and when FEV, is above 68% of 
predicted-NVL patients. (2) Dyspnea at peak exercise is the 
major symptom in VL patients, but it is not discriminate a 
respiratory from a cardiovascular limitation; (3) CPXT is 
the only reliable means for determining the cause of limita- 
tion in COPD patients with FEV, between 38% and 68%. 
To differentiate exercise ventilatory limitation from non- 
ventilatory causes, FEV, (i.e. PFT) and CPXT are best 
correlated when the FEV, is ~38% and >68% of predicted. 
Our data suggest that such a determination is not possible 
when FEV, is between 38% and 68% of predicted. 
Analysis of the pulmonary function parameters in both 
groups clearly indicated that FEV, was the most sensitive 
index for distinguishing VL from NVL patients. All 
patients with FEV, of less than 38% of predicted were VL. 
FEV, was less than 60% of predicted in most of the COPD 
patients whose exercise limitation was ventilatory in origin, 
and less than 68% of predicted in all the patients. On the 
other hand, all COPD patients with FEV, more than 68% 
of predicted were NVL. Carter et al. (21) found that the 
FEV, predicted exercise maximal ventilation (VE,,,) in 53 
patients with FEV, between 0.56 and 1.64 1. 
There was a significant correlation between the FEV, and 
the dyspnea index. In most patients with a dyspnea index of 
>80%, the FEV, was less than 60%. However, this finding 
should be interpreted with caution, because exercise MW, 
predicted by FEV, (i.e. I/E,,, predicted), varies signifi- 
cantly with tidal volume, end-expiratory lung volume and 
the pattern of respiratory muscle activation (22). 
While a significant correlation between the DLCO and 
the dyspnea index was apparent in our COPD patients, the 
scatter of the results was such that it was impossible to find 
two cutoff points distinguishing VL from NVL patients. 
While there were some patients in the VL group with a 
DLCO of more than 100% of predicted, all those with a 
DLCO of less than 50% of predicted were VL (100% 
specificity). Indeed, Augusti et al. (23) reported diffusion 
limitation of oxygen transfer in patients with severe COPD 
(FEV, ~36% of predicted). This finding is in agreement 
with the studies showing that significant arterial oxygen 
desaturation during exercise is likely in COPD patients if 
the DLCO is less than approximately 35% of the predicted 
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value, such that hypoxemia leads to breathlessness and 
exercise termination (12). 
Discomfort during breathing is generally assumed to 
limit exercise in patients with COPD. Although most 
patients with severe disease are restricted by dyspnea, about 
one-third are restricted by leg fatigue, either alone or 
combined with dyspnea (24). In the present study, dyspnea 
sensation was the limiting symptom in about half the 
patients with COPD (28/57) compared to only 15% (6/40) 
of the control group. 
It is possible that patients who reportedly discontinued 
exercise because of leg fatigue may have demonstrated 
better exercise performance and pulmonary function than 
patients who stopped because of dyspnea. Indeed, when 
the COPD patients were further divided by ventilatory 
capacity, dyspnea sensation proved to be the prominent 
limiting symptom in 61% of the VL group, and leg discom- 
fort was presenting in only 14%. These results demonstrate 
that not in all COPD patients with ventilatory limitation 
was dyspnea sensation the major reason for terminating 
maximal effort. Similarly, Mahler & Harver (4) reported 
that patients in whom leg fatigue was the limiting symptom, 
VO, and PFT values were greater than those who reported 
dyspnea as the major limiting symptom. Rampulla et al. 
(25) found that of 66 consecutive patients with chronic lung 
disease (COPD and interstitial lung disease), only 42% 
stopped exercise owing to dyspnea, 41% due to fatigue, and 
12% stopped because of cardiac limitation. The results are 
in contrast to those of Servera et al. (26) who reported that 
in most patients with COPD, even those with moderate 
or severe obstruction, exercise limitation was due to leg 
discomfort. Recently, it has been suggested that strength 
and endurance of respiratory and skeletal muscles were 
found to be significantly reduced in COPD patients 
(FEV, =43 rt 19% of predicted) who demonstrated early 
peripheral muscle fatigue during exercise (27). It has been 
suggested that in COPD patients, the high prevalence of 
local leg fatigue at end-exercise can be explained by loss of 
muscle mass (i.e. malnutrition, and sedentary life- 
style), impaired muscle perfusion, hypoxia, or myopathy 
owing to circulating cytokines (28). We therefore speculate 
that in our study COPD patients in addition to dyspnea, 
peripheral (limb and respiratory) muscle weakness could 
have contributed to exercise symptomatology. 
We therefore contend that the limiting symptoms of 
exercise performance in patients with COPD cannot serve 
as guide to the cause of the exercise limitation, even though 
dyspnea sensation is more common in those who are 
ventilatory limited. 
Conclusions 
Based on the findings of the present study we conclude that 
whereas in COPD patients with FEV, below 38% and 
above 68% of predicted is a good predictor of ventilatory 
and nonventilatory limitation respectively, CPXT should be 
supplemented in patients with a FEV, between 38% and 
68% of predicted. DLCO however, do not predict exercise 
limitation with any precision in both VL and NVL COPD 
patients. Furthermore, while peak exercise dyspnea is the 
most common limiting symptom in VL patients, it cannot 
serve as a reliable parameter in determining the cause of 
exercise limitation, nor it discriminate a respiratory from a 
cardiovascular limitation. The possible role of limb muscle 
function in exercise limitation in COPD patients merits 
future evaluation and investigation. 
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